- Novartis names new head of sales U.S.
- Walgreens partners with United Nations Foundation's Shot@Life campaign
- Novartis Consumer Health's return to shelf on track, Theraflu relaunching next
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Sandoz starts late-stage trial of Humira biosimilar
PITTSBURGH — Mylan has launched a generic treatment for breast cancer, the drug maker said Monday.
Mylan announced the launch of letrozole tablets in the 2.5-mg strength, an adjuvant treatment for postmenopausal women with hormone receptor-positive early-stage breast cancer.
The drug is the first generic version of Novartis’ Femara, which had sales of about $682 million in 2010, according to IMS Health.